PERTH, Australia, Sept. 13, 2017 /Weed Wire/ — The Board of Zelda Therapeutics Ltd (ASX: ZLD, Zelda or the Company) is pleased to announce it is making significant progress with its research programme in Chile.
Tag Archives: Clinical Trials
On May 23, 2017, Hound Labs Inc., a marijuana breathalyzer company in Oakland, announced that it has closed its Series B round of financing with $8.1 million from Benchmark, a California-based venture capital firm that has made successful early-stage investments in companies like Uber and Snapchat, among others.
OAKLAND, Calif., May 23, 2017 /Weed Wire/ — Hound Labs, Inc., creators of the patent-pending Hound® marijuana breathalyzer, announced today that Benchmark invested $8.1 million in the company.
The medical sector of the cannabis industry continues to explode behind constant research and innovative studies for identifying viable cancer treatments and other therapies for different ailments.
The phones at the Georgia Department of Public Health no longer ring off the hook with people calling to find doctors or asking questions about how the state’s medical marijuana registry works.
Most doctors approach medical marijuana with a great deal of uncertainty, because drug laws have hindered researchers’ ability to figure out what pot can and can’t do for sick patients.
In September 2014, The University of Utah’s Division of Pediatric Neurology and Primary Children’s Medical Center started the first of three clinical trials on the efficacy of Epidiolex, a nonpsychoactive cannabidiol-based drug from GW Pharmaceuticals (NASDAQ: GWPH).
The U.S. Drug Enforcement Agency has given the green light to a clinical study of smoked marijuana’s effectiveness for treating Post Traumatic Stress Disorder in veterans, according to the Multidisciplinary Association for Psychedelic Studies. Seventy-six U.S. veterans will participate in the study.
The Australian government has introduced legislation that would amend the Narcotics Drugs Act of 1967 to allow for the legal cultivation and distribution of medical marijuana.
Right before Christmas, on Dec. 23, 2015, the DEA released a press release quietly announcing a new federal advancement on cannabinoid research.
SAN DIEGO, Aug. 11, 2015 /Weed Wire/ — AXIM Biotechnologies, Inc. (OTC: AXIM) is a unique biotechnology corporation with a focus on global research, development and production of pharmaceutical, nutraceutical, food and cosmetic products – all derived from industrial hemp.
A recent study published in the Journal of the American Medical Association has suggested that medical marijuana may not be effective for many of the illnesses that supporters claim it helps.